News | June 03, 2013

This is the third Mevion S250 proton therapy system delivered


June 3, 2013 — Mevion Medical Systems has delivered the superconducting synchrocyclotron accelerator for its Mevion S250 proton therapy system under installation at the Peggy and Charles Stephenson Cancer Center at the University of Oklahoma.

This is the third single-room Mevion S250 proton therapy system delivered — all installed at leading academic institutions.

”We are delighted to receive this revolutionary machine that will allow us to deliver the same proton treatment as other larger conventional systems but at a fraction of the cost and size and with the most advanced clinical targeting technology” said Mike Samis, chairman of the University Hospitals Authority and Trust. “The addition of this advanced treatment option to our flagship cancer center continues to define the OU Cancer Institute as the state’s leading center of excellence.”

Following a five-day journey from Massachusetts to Oklahoma, the proton accelerator was brought into the Stephenson Cancer Center in only a few hours and will be installed on its gantry. The Mevion S250 is enhancing the center’s state-of-the-art radiation therapy department with a fully integrated proton therapy clinical treatment room. A second Mevion S250 treatment space has been reserved to support future clinical demand.

Powered by a TriNiobium Core, the Mevion S250 is a unique proton therapy system that provides the same precise, non-invasive treatment capabilities and advantages of conventional systems but with significantly reduced size, improved reliability, efficient clinical workflow and lower implementation and operational costs. With a footprint similar to an X-ray radiation therapy device, Mevion proton therapy can be easily integrated into any existing radiation therapy department.

For more information: www.mevion.com


Related Content

News | Radiation Dose Management

April 25, 2024 — BIOTRONIK, a leading global medical technology company specializing in innovative cardiovascular and ...

Time April 25, 2024
arrow
News | Artificial Intelligence

March 28, 2024 — As artificial intelligence (AI) makes its way into cancer care – and into discussions between ...

Time March 28, 2024
arrow
News | Prostate Cancer

March 27, 2024 — A minimally invasive treatment using MRI and transurethral ultrasound instead of surgery or radiation ...

Time March 27, 2024
arrow
Videos | Radiation Oncology

In the conclusion of this 3-part video series on recent advancements in diagnostic radiology, current editorial advisory ...

Time March 19, 2024
arrow
News | Breast Imaging

March 18, 2024 — QT Imaging Holdings, Inc., a medical device company engaged in research, development, and ...

Time March 18, 2024
arrow
Feature | Radiation Oncology | By Christine Book

Appreciating the considerable advances in the clinical application of artificial intelligence (AI) within healthcare ...

Time March 06, 2024
arrow
News | FDA

March 1, 2024 — Varian, a Siemens Healthineers company, announced that it has received 510(k) clearance from the U.S ...

Time March 01, 2024
arrow
News | Breast Imaging

February 22, 2024 — The FAST-Forward randomized trial from the UK found that ultrahypofractionated whole breast ...

Time February 22, 2024
arrow
News | Radiation Oncology

February 22, 2024 — The National Institutes of Health has launched a clinical trials network to evaluate emerging ...

Time February 22, 2024
arrow
News | Radiation Oncology

February 14, 2024 — Accuray Incorporated announced that the team at Quebec’s Montérégie Integrated Cancer Center, part ...

Time February 14, 2024
arrow
Subscribe Now